14 High Park Road, Kew, Richmond, TW9 4BH
Telephone: 020 8487 8292
Sorry, we're closed
Fully vaccinated children aged 12 to 15 can get an NHS COVID Pass letter for international travel.
The NHS COVID Pass letter for international travel is sent in the post and can be requested either:
Your GP cannot provide you with this letter or service.
We are no longer doing any COVID Vaccinations or Boosters here at the practice please either call 119 or Visit the NHS Website and check if you are eligible.
Covid-19 infections rates are rising across England with the latest test-and-trace figures showing 45% more infections week-on-week. The Covid-19 vaccines are the best way to protect yourself and others from becoming seriously ill. Millions of people across the UK have now received a Covid-19 vaccine, which is a safe and effective way to help fight coronavirus. The latest analysis by Public Health England shows that, after two doses, the Covid vaccines are over 90% effective against hospitalisation with the Delta variant-which is now dominant in the UK. We understand you may have questions about the vaccine. Our South West London NHS website has lots of information about the vaccine including answers to frequently asked questions.
There are number of vaccination events happening which you can access, with no need for an appointment. The most up-to-date information about these walk-in clinics, including locations and times, can be found on the South West London NHS website.
If these vaccination clinics are not convenient for you then you can also book an appointment at any other vaccination site across South West London via the NHS National Booking Service or by calling 119.
This priority list is as follows:
People with the following conditions are automatically deemed clinically extremely vulnerable:
5. all those 65 years of age and over
6. all individuals aged 16 years to 64 years with underlying health conditions. See table below
|Chronic respiratory disease||Individuals with a severe lung condition, including those with asthma that
requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and bronchopulmonary dysplasia (BPD).
|Chronic heart disease and vascular disease||Congenital heart disease, hypertension with cardiac complications, chronic
heart failure, individuals requiring regular medication and/or follow-up for
ischaemic heart disease. This includes individuals with atrial fibrillation,
peripheral vascular disease or a history of venous thromboembolism.
|Chronic Kidney Disease||Chronic kidney disease at stage 3, 4 or 5, chronic kidney failure, nephrotic
syndrome, kidney transplantation.
|Chronic liver disease||Cirrhosis, biliary atresia, chronic hepatitis.|
|Stroke, transient ischaemic attack (TIA). Conditions in which respiratory
function may be compromised due to neurological disease (e.g. polio
syndrome sufferers). This includes individuals with cerebral palsy, severe or
profound learning disabilities, Down’s Syndrome, multiple sclerosis,
epilepsy, dementia, Parkinson’s disease, motor neurone disease and related
or similar conditions; or hereditary and degenerative disease of the
nervous system or muscles; or severe neurological disability.
|Diabetes mellitus||Any diabetes, including diet-controlled diabetes.|
|Immunosuppression||Immunosuppression due to disease or treatment, including patients
undergoing chemotherapy leading to immunosuppression, patients
undergoing radical radiotherapy, solid organ transplant recipients, bone
marrow or stem cell transplant recipients, HIV infection at all stages,
multiple myeloma or genetic disorders affecting the immune system (e.g.
IRAK-4, NEMO, complement disorder, SCID).
Individuals who are receiving immunosuppressive or immunomodulating
biological therapy including, but not limited to, anti-TNF, alemtuzumab,
ofatumumab, rituximab, patients receiving protein kinase inhibitors or
PARP inhibitors, and individuals treated with steroid sparing agents such as
cyclophosphamide and mycophenolate mofetil.
Individuals treated with or likely to be treated with systemic steroids for
more than a month at a dose equivalent to prednisolone at 20mg or more
per day for adults.
Anyone with a history of haematological malignancy, including leukaemia,
lymphoma, and myeloma and those with systemic lupus erythematosus
and rheumatoid arthritis, and psoriasis who may require long term
Most of the more severely immunosuppressed individuals in this group
should already be flagged as CEV. Individuals who are not yet on the CEV
list but who are about to receive highly immunosuppressive interventions
or those whose level of immunosuppression is about to increase may be
therefore be offered vaccine alongside the CEV group, if therapy can be
safely delayed or there is sufficient time (ideally two weeks) before therapy
Some immunosuppressed patients may have a suboptimal immunological
response to the vaccine (see Immunosuppression and HIV).
dysfunction of the
|This also includes conditions that may lead to splenic dysfunction, such as
homozygous sickle cell disease, thalassemia major and coeliac syndrome
|Morbid obesity||Adults with a Body Mass Index ≥40 kg/m².|
|Severe mental illness||Individuals with schizophrenia or bipolar disorder, or any mental illness that
causes severe functional impairment.
|Adult carers||Those who are eligible for a carer’s allowance, or those who are the sole
or primary carer of an elderly or disabled person who is at increased risk of
COVID-19 mortality and therefore clinically vulnerable.
|Younger adults in
and residential care
|Many younger adults in residential care settings will be eligible for
vaccination because they fall into one of the clinical risk groups above (for
example learning disabilities). Given the likely high risk of exposure in these
settings, where a high proportion of the population would be considered
eligible, vaccination of the whole resident population is recommended.
Younger residents in care homes for the elderly will be at high risk of
exposure, and although they may be at lower risk of mortality than older
residents should not be excluded from vaccination programmes.
Please note: asthma does not automatically qualify you for a priority covid vaccine. Please read the criteria
7. all those 60 years of age and over
8. all those 55 years of age and over
9. all those 50 years of age and over